1. Clinical & Scientific Overview
Azelaic Acid (Cosmetic Derma Grade <=10%) (TIP-MED-000612, Reference Code [COS-08]) is classified under
Cosmetics & Cosmeceutical Ingredients (Cosmetics Rules, 2020) as a Cosmetic Science & Dermopharmaceutics • Dicarboxylic Acid Sebum & Tone-Conditioning Active.
Within the Indian regulatory and compendial framework, it is governed under Cosmetic at <=10% under Cosmetics Rules, 2020; 15% Gel and 20% Cream (Aziderm / Ezanic) are prescription dermatological drug formulations in India..
INCI Standard: Azelaic Acid (IS 4707 / Cosmetics Rules, 2020 Compliant)
Cosmetic suspensions/serums: 5% to 10%; pH 4.5–5.5
Dermopharmaceutics, INCI Formulation & Cosmetics Rules 2020 Compliance
Azelaic AcidDicarboxylic Acid Sebum & Tone-Conditioning Active
Cosmetic suspensions/serums: 5% to 10%; pH 4.5–5.5
Irritation, Sensitisation & Photoprotection Considerations: Mild transient pruritus, tingling, or dryness during the first 1–2 weeks; safe in pregnancy (unlike retinoids or hydroquinone).
Chemical Stability & Formulation Incompatibilities: Poorly soluble in water and oil (forms gritty suspensions unless micronised or solubilised as potassium azeloyl diglycinate at pH 4.8–5.5).
Statutory Cosmetic vs Drug Distinction (Cosmetics Rules, 2020 & BIS IS 4707): Cosmetic at <=10% under Cosmetics Rules, 2020; 15% Gel and 20% Cream (Aziderm / Ezanic) are prescription dermatological drug formulations in India.
3. Mechanism of Action & Pharmacodynamics
Naturally occurring saturated 9-carbon dicarboxylic acid that normalises follicular keratinisation, scavenges reactive oxygen species from neutrophils, and competitively inhibits hyperactive tyrosinase without depigmenting normal melanocytes.
4. Therapeutic Indications & Evidence-Supported Uses
- Cosmetic care for blemish-prone, redness-prone, and uneven-toned skin (at <=10% cosmetic strength)
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Cosmetic Formulation Concentration & pH Window: Cosmetic suspensions/serums: 5% to 10%; pH 4.5–5.5
Administration & Meal Timing: External topical use only (Cosmetic suspensions/serums: 5% to 10%; pH 4.5–5.5). Poorly soluble in water and oil (forms gritty suspensions unless micronised or solubilised as potassium azeloyl diglycinate at pH 4.8–5.5).
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Stratum corneum partitioning and epidermal retention governed by molecular weight (<500 Da rule), logP, and formulation pH; cosmetic ingredients are formulated for local epidermal/corneocyte conditioning without systemic pharmacological action.
Local epidermal enzymatic hydrolysis or oxidation where applicable (e.g., esterases for retinyl/tocopheryl esters).
Not applicable (topical cosmetic ingredient with negligible systemic exposure when used on intact skin).
Not applicable (topical external cosmetic use).
7. Contraindications, Precautions & High-Risk Warnings
- Known allergic contact dermatitis or hypersensitivity to Azelaic Acid
- Application to open wounds, abraded skin, or acute infectious dermatoses
- Mild transient pruritus, tingling, or dryness during the first 1–2 weeks; safe in pregnancy (unlike retinoids or hydroquinone).
Key Clinical Precautions: Mild transient pruritus, tingling, or dryness during the first 1–2 weeks; safe in pregnancy (unlike retinoids or hydroquinone).
8. Adverse Effects Profile
- Mild transient pruritus, tingling, or dryness during the first 1–2 weeks; safe in pregnancy (unlike retinoids or hydroquinone).
- Mild transient pruritus, tingling, or dryness during the first 1–2 weeks; safe in pregnancy (unlike retinoids or hydroquinone).
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Poorly soluble in water and oil (forms gritty suspensions unless micronised or solubilised as potassium azeloyl diglycinate at pH 4.8–5.5).
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Formulation Stability & Compatibility Check: Poorly soluble in water and oil (forms gritty suspensions unless micronised or solubilised as potassium azeloyl diglycinate at pH 4.8–5.5).
Pharmacist Patient Counselling Points:
- Perform a 24–48 hour forearm patch test before introducing a new active cosmeceutical onto facial skin.
- Apply broad-spectrum SPF 30+ PA+++ sunscreen every morning, especially when using AHAs, BHAs, retinol, or brightening actives.
- Cosmetic products clean, condition, or protect superficial skin appearance; persistent acne, melasma, rosacea, or eczema requires medical dermatology evaluation.
Storage, Stability & Dispensing Safeguards: Poorly soluble in water and oil (forms gritty suspensions unless micronised or solubilised as potassium azeloyl diglycinate at pH 4.8–5.5).
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Cosmetics Rules, 2020 (CDSCO, Ministry of Health & Family Welfare, Govt. of India); Bureau of Indian Standards (BIS) IS 4707 (Part 1 & Part 2) Classification of Cosmetic Raw Materials and Adjuncts.
Official Verification Portals: CDSCO — Cosmetics Division & Cosmetics Rules, 2020 • Bureau of Indian Standards (BIS) — IS 4707 Cosmetic Standards
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.